A subgroup signal sharpens the debate over how to treat ATTR-CM
A new secondary analysis from the phase 3 CARDIO-TTRansform trial suggests that eplontersen, an antisense therapy designed to reduce transthyretin production, may have a more defined role in transthyretin amyloid cardiomyopathy than the headline result from the overall study first implied. In the full trial population, eplontersen did not significantly reduce the primary composite endpoint. But in a prespecified analysis published in Nature Medicine, researchers report that baseline use of transthyretin stabilizers changed the treatment effect in a statistically significant way.
The practical implication is straightforward: patients who were not already taking a stabilizer appeared to benefit, while patients who entered the study on stabilizer therapy did not show the same signal. That does not settle the question of optimal sequencing or combination therapy, but it does narrow it. For physicians and drug developers working in ATTR-CM, the results point away from a simple assumption that combining a gene silencer with a stabilizer automatically produces better outcomes.
What the trial found
The study randomized 1,432 patients with ATTR-CM in a 1:1 design to receive either eplontersen at 45 mg every four weeks or placebo for as long as 140 weeks. According to the analysis, 57% of participants were already taking transthyretin stabilizers at baseline. The primary endpoint was a composite of cardiovascular mortality and recurrent cardiovascular events.
In the overall trial, eplontersen did not significantly reduce that primary composite endpoint. The secondary analysis focused on whether background stabilizer use influenced the drug’s effect. The answer was yes: the interaction between treatment effect and baseline stabilizer use reached statistical significance, with a reported interaction P value of 0.017.
Among patients who were not taking stabilizers at baseline, eplontersen was associated with a relative risk of 0.71 for the primary endpoint compared with placebo, with a 95% confidence interval of 0.54 to 0.93 and a P value of 0.012. In contrast, among patients already on stabilizers at baseline, the relative risk was 1.14, with a 95% confidence interval of 0.85 to 1.53 and a P value of 0.39. In plain terms, the drug appeared to help in the no-stabilizer group and did not show evidence of benefit in the group already receiving stabilizer therapy.
Why this matters for a growing disease area
ATTR-CM has moved from an underdiagnosed disorder to one of the most active cardiovascular drug markets in a relatively short time. That shift has been driven by better recognition of the disease, expanded imaging and diagnostic pathways, and the arrival of disease-modifying therapies. As more patients are identified earlier, treatment strategy becomes more important. The field is no longer only asking whether a therapy works, but for whom, when, and in what combination.
That is why this analysis matters even though it comes from a study that missed its primary endpoint overall. ATTR-CM treatments currently include stabilizers, which aim to keep transthyretin from misfolding, and gene silencers, which reduce the production of the protein itself. Clinically, it has been reasonable to assume that hitting both mechanisms at once could help. The new results challenge that assumption, or at least suggest that the benefit of a silencer may depend on whether a patient is already receiving a stabilizer.
The paper does not prove that stabilizers interfere with eplontersen, nor does it establish a causal biological explanation for the different subgroup results. But it does show that background therapy materially changed the observed outcome pattern in a large, randomized setting. That is enough to influence how clinicians interpret future data and how companies design subsequent studies.
Safety may keep the combination question alive
One reason this analysis is likely to draw close attention is that the safety profile remained favorable irrespective of stabilizer use at baseline. If a treatment shows a clear safety problem in combination, the clinical question becomes easier. That did not happen here, based on the source text. Instead, the findings create a more subtle problem: if combining the approaches appears safe but does not improve major outcomes, physicians and payers will want stronger evidence before embracing a more complex and potentially more expensive treatment path.
That makes future trial design especially important. Researchers may need to separate treatment-naive patients from those already receiving stabilizers, rather than pooling them and hoping subgroup patterns resolve later. Regulators, too, may look closely at whether label language or post-approval evidence should distinguish between add-on use and standalone use.
What can and cannot be concluded yet
There are clear limits to the findings. This is a secondary analysis, even though it was prespecified. That makes it more credible than an exploratory post hoc subgroup search, but it still does not carry the same weight as a trial designed from the start around stratified treatment strategies. The overall study’s failure to significantly reduce the primary endpoint also remains a central fact. Any clinical enthusiasm around the subgroup result will need to be tempered by that broader context.
At the same time, dismissing the result as noise would be too simplistic. The subgroup difference was not merely directional; it was accompanied by a statistically significant interaction test. In a field where combination approaches are often treated as intuitive upgrades, that is a meaningful finding. It suggests the therapeutic logic in ATTR-CM may be more conditional than many had hoped.
It also raises practical questions for current care pathways. If the benefit of eplontersen is concentrated among patients not already on stabilizers, clinicians may eventually need to think more carefully about treatment order and patient selection. That could affect how newly diagnosed patients are managed, especially if additional data reinforce the idea that one strategy works better as an alternative than as an add-on.
The broader industry signal
For the biotechnology sector, the message is larger than a single drug. ATTR-CM has become a proving ground for precision around mechanism, patient segmentation, and commercial positioning. Companies increasingly need to show not only that a therapy changes biomarkers or intermediate disease measures, but that it improves hard outcomes in the right slice of patients. The CARDIO-TTRansform secondary analysis suggests that broad combination narratives may not be enough.
That does not diminish the importance of eplontersen’s signal in untreated patients. If that benefit is confirmed and better characterized, it could still represent a clinically meaningful option for a sizable group. But it would place the drug in a more specific role than a universal add-on therapy for ATTR-CM.
For now, the paper sharpens the field’s central question rather than answering it completely. In ATTR-CM, mechanism still matters, but context may matter just as much. The next wave of evidence will need to show whether targeted use of gene silencing can convert this subgroup promise into a durable treatment strategy.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com